Literature DB >> 12197877

High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders.

S Jolles.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12197877      PMCID： PMC1906471          DOI： 10.1046/j.1365-2249.2002.01967.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  35 in total

1.  Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins.

Authors:  G G Tóth; M F Jonkman
Journal:  Br J Dermatol       Date:  1999-09       Impact factor: 9.302

2.  Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity.

Authors:  U Jappe; D Zillikens; B Bonnekoh; H Gollnick
Journal:  Br J Dermatol       Date:  2000-03       Impact factor: 9.302

3.  High-dose intravenous immune globulin is also effective in linear IgA disease.

Authors:  M M Kroiss; T Vogt; M Landthaler; W Stolz
Journal:  Br J Dermatol       Date:  2000-03       Impact factor: 9.302

4.  Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.

Authors:  N Sami; K C Bhol; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

5.  Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.

Authors:  A R Ahmed
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

6.  High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid.

Authors:  G Tappeiner; A Steiner
Journal:  J Am Acad Dermatol       Date:  1989-04       Impact factor: 11.527

7.  Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

Authors:  C S Foster; A R Ahmed
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

8.  Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy.

Authors:  A R Ahmed; J E Colón
Journal:  Arch Dermatol       Date:  2001-09

9.  High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases.

Authors:  K E Harman; M M Black
Journal:  Br J Dermatol       Date:  1999-05       Impact factor: 9.302

10.  Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy.

Authors:  E Letko; K Bhol; C S Foster; A R Ahmed
Journal:  Ophthalmology       Date:  2000-08       Impact factor: 12.079
View more
  9 in total

Review 1.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 3.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

4.  Intravenous Immunoglobulin: Revisited - My Experience.

Authors:  Sanjeev S Vaishampayan; Surendra Singh Bhati; Radha R Lachhiramani; Shivank Shrivastava; Prateek Jain; Ajay Singh Raghuwanshi
Journal:  Indian J Dermatol       Date:  2021 May-Jun       Impact factor: 1.494

Review 5.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

6.  The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis.

Authors:  Marta Baleva; Krasimir Nikolov
Journal:  Int J Rheumatol       Date:  2011-11-02

7.  Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report.

Authors:  Giovanni Angelini; Domenico Bonamonte; Alberta Lucchese; Gianfranco Favia; Rosario Serpico; Abraham Mittelman; Simone Simone; Animesh A Sinha; Darja Kanduc
Journal:  J Transl Med       Date:  2006-10-24       Impact factor: 5.531

8.  Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI.

Authors:  Fabian Bohländer; Dennis Riehl; Sabrina Weißmüller; Marcus Gutscher; Jörg Schüttrumpf; Stefanie Faust
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 9.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.